IL1B and non-small cell lung carcinoma: The CANOPY program including four phase II or III randomized studies was designed to evaluate the effects of canakinumab (a IgG1k monoclonal anti-human antibody that selectively binds and neutralizes IL-1β) in the treatment of NSCLC [92].